US FDA oncology drug approvals in 2014
- 22 May 2015
- journal article
- review article
- Published by Taylor & Francis in Future Oncology
- Vol. 11 (13) , 1931-1945
Abstract
Cancer is a close second to heart disease for cause of death in the USA, and could soon surpass heart disease as the population ages and the incidence of cancer continues to increase. While heart disease can be addressed through behavior modification and education (e.g., smoking cessation, dietary changes, exercises that promote cardiovascular fitness), pharmacology and improved surgical devices and methods, cancer ultimately requires improved and novel drug treatments to bring mortality rates down. In 2014, the US FDA approved 17 drugs and/or drug combinations in 12 disease sites for a total of 19 indications in melanoma, hematologic malignancies, gastrointestinal carcinoma, non-small-cell lung cancer, gynecologic malignancies and lymphoma/lymphoproliferative disorders.Keywords
This publication has 27 references indexed in Scilit:
- Improved Survival with Bevacizumab in Advanced Cervical CancerNew England Journal of Medicine, 2014
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trialThe Lancet, 2014
- Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2013
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2013
- A Step Toward More Accurate Dosing for Mercaptopurine in Childhood Acute Lymphoblastic LeukemiaThe Journal of Clinical Pharmacology, 2012
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian CancerNew England Journal of Medicine, 2012
- Review of Oncology and Hematology Drug Product Approvals at the US Food and Drug Administration Between July 2005 and December 2007JNCI: Journal of the National Cancer Institute, 2010
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004
- Oncology's trialsNature Reviews Drug Discovery, 2003
- Histone deacetylases and cancer: causes and therapiesNature Reviews Cancer, 2001